RT Journal Article
SR Electronic
T1 Performance of Repeat BinaxNOW SARS-CoV-2 Antigen Testing in a Community Setting, Wisconsin, November-December 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.05.21254834
DO 10.1101/2021.04.05.21254834
A1 Melisa M. Shah
A1 Phillip P. Salvatore
A1 Laura Ford
A1 Emiko Kamitani
A1 Melissa J. Whaley
A1 Kaitlin Mitchell
A1 Dustin W. Currie
A1 Clint N. Morgan
A1 Hannah E. Segaloff
A1 Shirley Lecher
A1 Tarah Somers
A1 Miriam E. Van Dyke
A1 John Paul Bigouette
A1 Augustina Delaney
A1 Juliana DaSilva
A1 Michelle O’Hegarty
A1 Lauren Boyle-Estheimer
A1 Fatima Abdirizak
A1 Sandor E. Karpathy
A1 Jennifer Meece
A1 Lynn Ivanic
A1 Kimberly Goffard
A1 Doug Gieryn
A1 Alana Sterkel
A1 Allen Bateman
A1 Juliana Kahrs
A1 Kimberly Langolf
A1 Tara Zochert
A1 Nancy W. Knight
A1 Christopher H. Hsu
A1 Hannah L. Kirking
A1 Jacqueline E. Tate
YR 2021
UL http://medrxiv.org/content/early/2021/04/09/2021.04.05.21254834.abstract
AB Repeating the BinaxNOW antigen test for SARS-CoV-2 by two groups of readers within 30 minutes resulted in high concordance (98.9%) in 2,110 encounters. BinaxNOW test sensitivity was 77.2% (258/334) compared to real-time reverse transcription-polymerase chain reaction. Repeating antigen testing on the same day did not significantly improve test sensitivity while specificity remained high.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. See e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. 241(d); 5 U.S.C. 552a; 44 U.S.C. 3501 et seq.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request.